Advertisement
Australia markets closed
  • ALL ORDS

    7,974.80
    -27.70 (-0.35%)
     
  • ASX 200

    7,724.30
    -25.40 (-0.33%)
     
  • AUD/USD

    0.6609
    -0.0029 (-0.43%)
     
  • OIL

    78.59
    -0.03 (-0.04%)
     
  • GOLD

    2,349.70
    +31.70 (+1.37%)
     
  • Bitcoin AUD

    98,733.28
    -2,512.34 (-2.48%)
     
  • CMC Crypto 200

    1,371.85
    -46.02 (-3.25%)
     
  • AUD/EUR

    0.6176
    +0.0004 (+0.06%)
     
  • AUD/NZD

    1.0772
    +0.0019 (+0.18%)
     
  • NZX 50

    11,864.89
    -7.75 (-0.07%)
     
  • NASDAQ

    19,629.86
    +52.94 (+0.27%)
     
  • FTSE

    8,146.86
    -16.81 (-0.21%)
     
  • Dow Jones

    38,535.26
    -111.84 (-0.29%)
     
  • DAX

    18,002.02
    -263.66 (-1.44%)
     
  • Hang Seng

    17,941.78
    -170.85 (-0.94%)
     
  • NIKKEI 225

    38,814.56
    +94.09 (+0.24%)
     

uniQure First Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags

uniQure (NASDAQ:QURE) First Quarter 2024 Results

Key Financial Results

  • Revenue: US$8.49m (up 59% from 1Q 2023).

  • Net loss: US$65.6m (loss narrowed by 15% from 1Q 2023).

  • US$1.36 loss per share (improved from US$1.63 loss in 1Q 2023).

earnings-and-revenue-growth
earnings-and-revenue-growth

All figures shown in the chart above are for the trailing 12 month (TTM) period

uniQure Revenues Beat Expectations, EPS Falls Short

Revenue exceeded analyst estimates by 26%. Earnings per share (EPS) missed analyst estimates by 7.6%.

Looking ahead, revenue is forecast to grow 38% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Biotechs industry in the US.

ADVERTISEMENT

Performance of the American Biotechs industry.

The company's shares are up 4.5% from a week ago.

Risk Analysis

You should always think about risks. Case in point, we've spotted 2 warning signs for uniQure you should be aware of.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.